- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06686394
전이되어 수술로 제거할 수 없는 HER2 양성 유방암 참가자의 Patritumab Deruxtecan과 다른 항암제에 대한 연구(MK-1022-009)
HERTHENA-Breast-01: HER2 양성 절제 불가능한 국소 진행성 유방암 또는 전이성 유방암 참가자를 대상으로 Patritumab Deruxtecan의 안전성 및 항종양 활성을 평가하기 위한 1b/2상, 다기관, 공개 라벨, 용량 결정 연구
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
연구 개요
상태
상세 설명
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Toll Free Number
- 전화번호: 1-888-577-8839
- 이메일: Trialsites@msd.com
연구 장소
-
-
-
Seoul, 대한민국, 03080
- 모병
- Seoul National University Hospital ( Site 0030)
-
연락하다:
- Study Coordinator
- 전화번호: 82-2-2072-0850
-
Seoul, 대한민국, 05505
- 모병
- Asan Medical Center ( Site 0031)
-
연락하다:
- Study Coordinator
- 전화번호: +82-2-1688-7575
-
-
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
연락하다:
- Study Coordinator
- 전화번호: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute ( Site 0050)
-
연락하다:
- Study Coordinator
- 전화번호: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08901
- 모병
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
연락하다:
- Study Coordinator
- 전화번호: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29605
- 모병
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
연락하다:
- Study Coordinator
- 전화번호: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- Inova Schar Cancer Institute ( Site 0051)
-
연락하다:
- Study Coordinator
- 전화번호: 571-472-4724
-
-
-
-
Camden
-
London, Camden, 영국, NW1 2PG
- 모병
- University College London Hospital ( Site 0041)
-
연락하다:
- Study Coordinator
- 전화번호: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, 영국, G12 0YN
- 모병
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
연락하다:
- Study Coordinator
- 전화번호: +441413017000
-
-
London, City of
-
London, London, City of, 영국, EC1A 7BE
- 모병
- St Bartholomew s Hospital ( Site 0040)
-
연락하다:
- Study Coordinator
- 전화번호: +442073777000
-
-
-
-
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus ( Site 0011)
-
연락하다:
- Study Coordinator
- 전화번호: 04-7776234
-
Petah Tikva, 이스라엘, 4941492
- 모병
- Rabin Medical Center ( Site 0012)
-
연락하다:
- Study Coordinator
- 전화번호: +972-505533121
-
Ramat Gan, 이스라엘, 5265601
- 모병
- Sheba Medical Center ( Site 0010)
-
연락하다:
- Study Coordinator
- 전화번호: 03-5304498
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 467-8602
- 모병
- Nagoya City University Hospital ( Site 0020)
-
연락하다:
- Study Coordinator
- 전화번호: +81-52-851-5511
-
-
-
-
Ontario
-
Kingston, Ontario, 캐나다, K7L 2V7
- 모병
- Kingston General Hospital ( Site 0061)
-
연락하다:
- Study Coordinator
- 전화번호: 6135336541
-
Toronto, Ontario, 캐나다, M5G 2M9
- 모병
- Princess Margaret Cancer Centre ( Site 0001)
-
연락하다:
- Study Coordinator
- 전화번호: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3T 1E2
- 모병
- Jewish General Hospital ( Site 0003)
-
연락하다:
- Study Coordinator
- 전화번호: 514-340-8222
-
Montreal, Quebec, 캐나다, H2X 3E4
- 모병
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
연락하다:
- Study Coordinator
- 전화번호: (514)890-8000 x20737
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
다른 이름들:
Trastuzumab administered via IV infusion
다른 이름들:
Trastuzumab biosimilar administered via IV infusion
다른 이름들:
|
|
실험적: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
다른 이름들:
Trastuzumab administered via IV infusion
다른 이름들:
Trastuzumab biosimilar administered via IV infusion
다른 이름들:
Pertuzumab administered via IV infusion |
|
실험적: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
다른 이름들:
Trastuzumab administered via IV infusion
다른 이름들:
Trastuzumab biosimilar administered via IV infusion
다른 이름들:
Tucatinib administered as oral tablets |
|
실험적: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
다른 이름들:
Trastuzumab administered via IV infusion
다른 이름들:
Trastuzumab biosimilar administered via IV infusion
다른 이름들:
Pertuzumab administered via IV infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
기간: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
기간: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
기간: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
기간: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
기간: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
기간: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
기간: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
기간: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
기간: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
공동 작업자 및 조사자
협력자
수사관
- 연구 책임자: Medical Director, Merck Sharp & Dohme LLC
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 1022-009
- MK-1022-009 (기타 식별자: MSD)
- jRCT2041250022 (레지스트리 식별자: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (레지스트리 식별자: EU CT)
- U1111-1346-4321 (레지스트리 식별자: UTN)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .